COMMUNIQUÉS West-GlobeNewswire

TESARO, Inc. Provides Notice of Fundamental Change, Conversion Rate Adjustment pursuant to Make-Whole Adjustment Event and Supplemental Indenture

24/01/2019 - 14:00

WALTHAM, Mass., Jan. 24, 2019 (GLOBE NEWSWIRE) -- TESARO, Inc. (the “ Company ” or “ TESARO ”), an oncology-focused biopharmaceutical company, today announced that pursuant to the terms of the Indenture and the First [...]

InspireMD Announces Presentation of Interim Data from Investigator-Initiated Study Comparing CGuard™ EPS with a Conventional Open-Cell Carotid Stent

24/01/2019 - 14:00

CGuard™ EPS shows encouraging interim results verses a conventional carotid stent in absence of any adverse clinical events in the CGuard™ arm Data presented at the LINC 2019 Congress in Leipzig, Germany TEL AVIV, [...]

Pascal Biosciences Commences Cannabinoid Testing of Human Volunteers and Patients

24/01/2019 - 14:00

VANCOUVER, British Columbia, and SEATTLE, Jan. 24, 2019 (GLOBE NEWSWIRE) -- Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”), a drug discovery and development company, today announced the testing of [...]

Meridian Bioscience Reports First Quarter 2019 Operating Results, Declares Regular First Quarter Cash Dividend, and Provides Updated Fiscal 2019 Guidance

24/01/2019 - 13:30

CINCINNATI, Jan. 24, 2019 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the first quarter ended December 31, 2018. First Quarter 2019 Highlights: Total revenue [...]

AIT Enters into $32.5 million Commercial Licensing Agreement with Circassia Pharmaceuticals for Its Novel Nitric Oxide Generator and Delivery System for Use in the Hospital Setting in the United States and China

24/01/2019 - 13:00

Additionally, AIT to garner a 15%-20% royalty on gross profit AIT will immediately request to be listed on the NASDAQ stock exchange PMA submission on track for the second quarter of 2019 Company to host a call today, [...]

Neurology Publishes Study Reporting Significant Improvements in Duchenne Muscular Dystrophy Patients Treated with Capricor’s Novel Cell Therapy

24/01/2019 - 13:00

Sustained Cardiac and Skeletal Muscle Function Improvements Shown after a Single Dose of CAP-1002 LOS ANGELES, Jan. 24, 2019 (GLOBE NEWSWIRE) -- Neurology ®, an international peer-reviewed journal, on Wednesday [...]

AxoGen to Participate at AAHS ASPN ASRM 2019 Annual Meetings

24/01/2019 - 13:00

The growing body of clinical evidence supporting the company’s platform for nerve repair will be featured in several presentations during the scientific sessions ALACHUA, Fla., Jan. 24, 2019 (GLOBE NEWSWIRE) -- AxoGen, [...]

NeuroMetrix Reports Q4 and Full Year 2018 Financial Results

24/01/2019 - 13:00

WALTHAM, Mass., Jan. 24, 2019 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO), today reported financial and business highlights for the quarter and year ended December 31, 2018. The Company develops and markets [...]

Asterias Provides Top Line 12 Month Data Update for its OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury

24/01/2019 - 13:00

FREMONT, Calif., Jan. 24, 2019 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated [...]

Auxly Signs Definitive Agreement With Curative Cannabis

24/01/2019 - 13:00

VANCOUVER, British Columbia, Jan. 24, 2019 (GLOBE NEWSWIRE) -- Auxly Cannabis Group Inc. (TSX.V: XLY) (OTCQX: CBWTF) (the " Company ") is pleased to announce that the Company has signed a definitive agreement (the “ [...]

Emergent BioSolutions Announces Appointment of Robert G. Kramer, Sr. to Its Board of Directors

24/01/2019 - 13:00

GAITHERSBURG, Md., Jan. 24, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the appointment of Robert G. Kramer, Sr. to the company’s Board of Directors. Mr. Kramer currently serves as [...]

Intellia Therapeutics Names Fred Cohen, M.D., to Board of Directors

24/01/2019 - 13:00

CAMBRIDGE, Mass., Jan. 24, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and [...]

Invitation to C-RAD Web Presentation Year-end Report 2018

24/01/2019 - 09:04

Presentation of the report for the fiscal year 2018: Date: Friday February 8, 2019 / kl. 13:00 CET Venue: Online Presentation Topic: C-RAD Year-end Report 2018 Procedure: Please register online through the website: [...]

FIT Biotech Oy: FIT Biotech plans a reverse share split

24/01/2019 - 08:21

FIT Biotech Oy Company release 24.1.2019 at 09:20 am EET FIT Biotech plans a reverse share split FIT Biotech Oy ("Company", FITBIO: FN Finland) plans to reduce the number of all its shares through a reverse share split [...]

Annual report 2018

24/01/2019 - 08:07

Please see attached file Attachment The_Novozymes_Report_2018

Group financial statement for 2018

24/01/2019 - 08:04

Read the full announcement in PDF Attachment 2019_01_Q42018_CompanyAnnouncement_EN_FINAL

Succès du traitement par bermekimab de l’hidrasadénite suppurée, avec notamment une nette diminution des douleurs

24/01/2019 - 07:50

Bermekimab traite les patients atteints d’hidrasadénite suppurée, même ceux en échec par un traitement biologique avancé AUSTIN, Texas, 24 janv. 2019 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ : XBIT) a annoncé aujourd’hui [...]

Bavarian Nordic Advances Development of Equine Encephalitis Virus Vaccine

24/01/2019 - 07:31

COPENHAGEN, Denmark, January 24, 2019 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) reports further progress in the development of a prophylactic vaccine against the equine encephalitis virus - a rare, but potentially [...]

Basilea announces collaboration to study derazantinib and atezolizumab (Tecentriq®) in urothelial cancer

24/01/2019 - 07:16

Basel, Switzerland, January 24, 2019 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that it entered into a collaboration with Roche (SIX: RO, ROG) to explore a combination of Basilea's derazantinib and Roche's [...]